Clinical

Articles

Previously treated patients with HLA-A*02:01-positive metastatic uveal melanoma  saw survival prediction improvements with ctDNA when compared to RECIST 1.1.

ctDNA Improved Predictor of Survival for Previously Treated Metastatic Uveal Melanoma

The use of adjuvant pembrolizumab resulted in a recurrence-free survival benefit for patients with resected high-risk stage II melanoma. 

Reduction In Disease Recurrence, Death With Adjuvant Pembrolizumab Noted in Resected High-Risk Stage II Melanoma

Patients with previously untreated metastatic or unresectable melanoma achieved promising benefit following treatment with relatlimab/nivolumab combination therapy.


Addition of Relatlimab to Nivolumab Yields Longer TFI and Improved PFS2 in Metastatic or Unresectable Melanoma

This clinical quandary discusses oligoprogressive disease in metastatic melanoma and how treatment with immunotherapy and targeted therapy affect the disease. 

Oligoprogression After Immunotherapy and Targeted Therapy in Metastatic Melanoma

Tebentafusp has demonstrated promising responses in metastatic uveal melanoma, leading to FDA and European Medicines Agency approval of a biologics license application and marketing authorization application for the agent.

FDA Accepts Biologics License Application for Tebentafusp in Metastatic Uveal Melanoma

Gut microbes may help to predict adverse effects and outcomes in patients with advanced melanoma who are being treated with dual immune checkpoint inhibitors.

Gut Microbes May Have an Association With Toxicity Related to Combination Immune Checkpoint Inhibitors in Advanced Melanoma

The results from a phase 1 trial that focused on a second cohort of patients with unresectable or metastatic melanoma identified positive safety and promising topline survival outcomes when treated with the combination of UV1 and pembrolizumab.

Positive Results Observed With UV1 Cancer Vaccine Plus Pembrolizumab in Metastatic Melanoma

According to the results of the phase 2 KEYNOTE-629 trial, patients with locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma appear to receive promising anti-tumor benefit from pembrolizumab.

Pembrolizumab Elicits Robust, Durable Activity in Locally Advanced or Recurrent/Metastatic cSCC

Pembrolizumab met its primary end point of prolonged recurrence-free survival in the phase 3 KEYNOTE-716 trial for patients with stage II resected high-risk melanoma. 

Pembrolizumab Prolongs Recurrence-Free Survival Compared With Placebo in Stage II Resected High-Risk Melanoma

Immunotherapy agent nemvaleukin alfa was granted an FDA fast track designation for the treatment of patient’s mucosal melanoma for previously undergone treatment with an anti-PD-L1 therapy. 

Melanoma | Topics